SEC Form 4 · accession 0000899243-18-006219
Clovis Oncology, Inc. · CLVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick J Mahaffy
Officer — See Remarks · Director
Period of report
Mar 1, 2018
Accepted (ET)
Mar 2, 2018 · 6:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001466301
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $58.43 | Mar 1, 2018 | A | 120,000 | A | — | Mar 1, 2028 | Common Stock | 120,000 | 120,000 | D |
Explanation of responses
- F1The option shall vest as to 25% of the shares on March 1, 2019, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
Remarks
President and Chief Executive Officer